Today: 20 May 2026
Browse Category

NYSE:HUM 29 January 2026 - 12 May 2026

UnitedHealth Stock Climbs as Investors Reprice the Turnaround, Not Just the Latest Headline

UnitedHealth Stock Climbs as Investors Reprice the Turnaround, Not Just the Latest Headline

UnitedHealth shares climbed 3.1% to $396.45 Tuesday after unveiling a new Optum Rx fee-based pricing model and raising 2026 profit guidance. The company reported Q1 revenue of $111.7 billion and adjusted earnings of $7.23 per share. Management said fundamentals are improving but described the turnaround as ongoing. Investors responded to both the PBM overhaul and stronger earnings outlook.
12 May 2026
····
Humana Stock Jumps 11% as Medicare Advantage Hopes Put HUM Shares Back in Play

Humana Stock Jumps 11% as Medicare Advantage Hopes Put HUM Shares Back in Play

Humana shares surged 11.27% to $274.96 on Friday, following CVS’s raised 2026 profit outlook tied to improved medical-cost control. Humana’s own 2026 forecast remains under pressure from lower Medicare Star Ratings and limited funding. First-quarter revenue rose to $39.65 billion, but adjusted earnings fell to $10.31 per share. The company maintained its full-year adjusted earnings forecast at at least $9 a share.
9 May 2026
····
Why Humana Stock’s 25% Rally Is Facing a Profit-Cut Reality Check

Why Humana Stock’s 25% Rally Is Facing a Profit-Cut Reality Check

Humana cut its 2026 GAAP EPS forecast to at least $8.36, down from $8.89, but kept its adjusted profit outlook at $9.00. Shares last traded at $247.12, up over 25% in a month, pushing the price-to-earnings ratio to 26.4. First-quarter revenue rose to $39.65 billion, while adjusted EPS fell to $10.31. Medicare Advantage accounts for about 80% of Humana’s revenue.
8 May 2026
·
Humana Stock Drops After Earnings Beat: Medicare Advantage Headwind Keeps Pressure On

Humana Stock Drops After Earnings Beat: Medicare Advantage Headwind Keeps Pressure On

Humana beat first-quarter profit estimates, earning $10.31 per share adjusted, but shares fell over 6% premarket after it kept its 2026 profit outlook unchanged and cut its GAAP earnings forecast. Revenue rose to $39.65 billion. The insurer cited lower Medicare Star Ratings for the earnings decline and said medical and pharmacy costs are “slightly better” than expected. Competitors Centene, UnitedHealth, and Elevance recently raised their annual forecasts.
29 April 2026
··
UnitedHealth Stock Jumps as Centene Results Put Insurer Turnaround Back in Play

UnitedHealth Stock Jumps as Centene Results Put Insurer Turnaround Back in Play

UnitedHealth Group shares rose about 4% Tuesday after Centene raised its profit forecast, fueling optimism that medical-cost pressures may be easing for large insurers. UnitedHealth last week lifted its 2026 profit outlook and reported a first-quarter medical care ratio of 83.9%. Centene’s medical loss ratio came in below analyst estimates. UnitedHealth’s Optum unit continues to face cost and contract challenges.
28 April 2026
·····
US Stock Market Today: S&P 500, Dow, Nasdaq Slip as Oil Jumps and Fed Uncertainty Caps Rally

US Stock Market Today: S&P 500, Dow, Nasdaq Slip as Oil Jumps and Fed Uncertainty Caps Rally

The S&P 500 fell 0.32% to 7,086.48 Tuesday afternoon as rising oil prices and Treasury yields erased early gains. Brent crude climbed again after a 5.6% jump Monday, following U.S.-Iran ceasefire tensions. UnitedHealth raised its full-year outlook, and Amazon pledged up to $25 billion in Anthropic. March retail sales rose 1.7%, the biggest increase in a year.
21 April 2026
··········
UnitedHealth Stock Slides Again as April Earnings Loom, Putting UNH Valuation Under New Scrutiny

UnitedHealth Stock Slides Again as April Earnings Loom, Putting UNH Valuation Under New Scrutiny

UnitedHealth Group shares dropped over 4% Friday to $257.04, deepening losses after a 1.6% fall earlier in the week. Humana, Elevance, and Cigna also declined, while the Health Care Select Sector SPDR ETF slipped 1.5%. Analysts expect UnitedHealth’s first-quarter profit to fall 8.1% from last year, with investors focused on April 21 results for signs of easing medical costs.
27 March 2026
·····
UnitedHealth (UNH) stock price rises as markets slide — Medicare Advantage deadlines and Humana warning in focus

UnitedHealth (UNH) stock price rises as markets slide — Medicare Advantage deadlines and Humana warning in focus

UnitedHealth shares climbed nearly 2% to $284.37 Thursday, bucking a broad market selloff as investors focused on Medicare Advantage policy signals. Humana warned of a 2026 profit hit from lower Medicare Advantage “star” ratings, missing analyst expectations. All major U.S. indexes fell over 1%. Key Medicare rate decisions are due Feb. 25 and April 6.
12 February 2026
··
UnitedHealth stock price slips after hours as investors brace for early-April Medicare rate call

UnitedHealth stock price slips after hours as investors brace for early-April Medicare rate call

UnitedHealth shares slipped 0.3% to $275.70 in after-hours trading Monday, while the S&P 500 and Nasdaq closed higher. Healthcare stocks lagged as investors eyed Medicare Advantage reimbursement and cost trends ahead of key policy updates. Humana dropped 2.3%, CVS Health fell 3.3%, and Cigna rose 0.8%. UnitedHealth last month warned of its first revenue decline in decades if proposed Medicare rates hold.
10 February 2026
····
UnitedHealth stock heads into Monday after UNH’s 3% jump — what investors watch next

UnitedHealth stock heads into Monday after UNH’s 3% jump — what investors watch next

UnitedHealth shares rose 3% Friday to $276.65 after a volatile week for managed-care stocks. Investors await insurer earnings from CVS Health on Feb. 10 and Humana on Feb. 11 for updates on Medicare Advantage trends. The Centers for Medicare and Medicaid Services has proposed a 0.09% payment increase for 2027 plans. The comment period on the 2027 rate notice closes Feb. 25.
8 February 2026
···
UnitedHealth stock rebounds after hours as UNH recoups losses; Medicare rate debate looms

UnitedHealth stock rebounds after hours as UNH recoups losses; Medicare rate debate looms

UnitedHealth shares rose 3.4% to $277.57 Friday and gained another 3% after hours, rebounding after a volatile week for health insurers. Mizuho cut its price target on the stock to $350, citing delayed earnings recovery. Medicare Advantage rates and medical-cost trends remain key concerns. The Dow closed above 50,000, marking the strongest market gains in months.
7 February 2026
····
UnitedHealth stock falls again after FTC insulin deal puts OptumRx back in focus

UnitedHealth stock falls again after FTC insulin deal puts OptumRx back in focus

UnitedHealth shares fell nearly 3% to $275.92 in after-hours trading Wednesday after the FTC announced a 10-year insulin pricing settlement with Cigna’s Express Scripts, increasing scrutiny on OptumRx and CVS Caremark. Investors are watching for an FTC oral argument Feb. 5 and a House hearing on drug prices Feb. 11. CVS and Cigna shares also declined. UnitedHealth did not comment.
5 February 2026
·····
UnitedHealth stock bounces even after Truist, JPMorgan trim targets as Medicare Advantage rates loom

UnitedHealth stock bounces even after Truist, JPMorgan trim targets as Medicare Advantage rates loom

UnitedHealth shares rose 1% to $289.75 Monday, outperforming peers as Humana, Elevance, and Cigna declined. Truist and JPMorgan cut price targets but kept positive ratings. Investors focused on Medicare Advantage payment rates and 2026 cost trends after last week’s sector sell-off. Final 2027 Medicare Advantage rates are expected in April.
2 February 2026
·······
UnitedHealth stock slips after-hours as PBM fee disclosure rule adds fresh pressure on UNH

UnitedHealth stock slips after-hours as PBM fee disclosure rule adds fresh pressure on UNH

UnitedHealth shares fell 0.6% to $292.29 in after-hours trading Thursday after the U.S. Labor Department proposed new disclosure rules for pharmacy benefit managers. The proposal would require PBMs to reveal fee and compensation details. Investors are also closely watching upcoming Medicare Advantage rate decisions. Related health insurer stocks showed mixed movement late Thursday.
30 January 2026
·····
Elevance Health stock rises as ELV steadies after cautious 2026 outlook and Medicare rate jitters

Elevance Health stock rises as ELV steadies after cautious 2026 outlook and Medicare rate jitters

Elevance Health shares rose 1% to $345.44 Thursday, leading gains in managed-care stocks after policy and earnings volatility. The company forecast 2026 adjusted EPS of at least $25.50, below analyst expectations, and warned of revenue declines amid Medicaid and ACA headwinds. Medicare Advantage payments are set for a minimal 0.09% increase in 2027, rattling the sector. ACA enrollment for 2026 dropped to about 23 million as subsidies ended.
29 January 2026
·····
1 2 3

Stock Market Today

  • Target Sales and Stock Price Rise in 2026: Is a Retail Comeback Underway?
    May 20, 2026, 9:02 AM EDT. Target Corp, the Minneapolis-based retailer, is showing signs of a financial turnaround in 2026. Despite facing boycott calls last year after reducing diversity, equity, and inclusion (DEI) initiatives, the company's sales and stock price have been steadily increasing. This upswing could indicate a possible comeback for the retail giant as it navigates shifting consumer sentiment and operational challenges.

Latest articles

NextNRG Shares Double as Record April Sales Drive Gains

NextNRG Shares Double as Record April Sales Drive Gains

20 May 2026
NextNRG Inc. shares fell to $0.73 in premarket trading Wednesday after doubling Tuesday, as investors reacted to record April revenue of $9.4 million and a 64% jump in gross profit. The company reported just $208,048 in cash at March 31 and is seeking new capital. Net loss for the first quarter widened to $10.8 million despite higher sales. Results are preliminary and unaudited.
GCL Global up after ADATA invests $10M; Nasdaq $1 rule still ahead

GCL Global up after ADATA invests $10M; Nasdaq $1 rule still ahead

20 May 2026
GCL Global Holdings said ADATA invested another $10 million in its 4Divinity unit, bringing total disclosed ADATA commitments since December to $23 million. GCL shares traded at about 80 cents in U.S. premarket, up from Tuesday’s 43-cent close, but still below Nasdaq’s $1 minimum bid rule, which it must meet by Sept. 14.
Analog Devices heads into AI test after record quarter, $1.5 billion deal

Analog Devices heads into AI test after record quarter, $1.5 billion deal

20 May 2026
Analog Devices reported fiscal second-quarter revenue up 37% to $3.62 billion, beating estimates, with adjusted EPS at $3.09. The company forecast third-quarter revenue of $3.9 billion, above Wall Street expectations, and announced a $1.5 billion cash deal to acquire Empower Semiconductor to expand in AI power delivery.
Go toTop